Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
NEW YORK, Dec. 16, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) securities between February 10, 2014 and November 9, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/alexion-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Alexion made false and/or misleading statements and/or failed to disclose: (1) that the Company employed improper sales practices with respect to its product Soliris; (2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times.
On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. The Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this news was announced, shares of Alexion fell in value, causing investors harm.
If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/alexion-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
